Modality
Cell Therapy
MOA
Menini
Target
EZH2
Pathway
Lipid Met
SCD
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
~Jul 2017
→ ~Oct 2018
Phase 2
~Jan 2019
→ ~Apr 2020
Phase 3
~Jul 2020
→ ~Oct 2021
NDA/BLA
Jan 2022
→ Nov 2027
NDA/BLACurrent
NCT05132646
1,797 pts·SCD
2022-01→2027-11·Recruiting
1,797 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-081.6y awayPh3 Readout· SCD
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-11-08 · 1.6y away
SCD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05132646 | NDA/BLA | SCD | Recruiting | 1797 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 | |
| SLD-1824 | Solid Bio | Phase 2 | EZH2 | |
| TXG-6755 | 10x Genomics | Approved | CD123 | |
| Zoricapivasertib | CSL Limited | Phase 2 | HER2 |